UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

MYCN and ALKF1174L are sufficient to drive neuroblastoma development from neural crest progenitor cells

Oncogene, 2013-02, Vol.32 (8), p.1059-1065

2013

Volltextzugriff (PDF)

Advancement of the gold standard: ishage protocol combined with t and b cell analysis as mulitflex flow cytometry assay for standard cellular products and ATMPS

Cytotherapy (Oxford, England), 2021-05, Vol.23 (5), p.S200-S201

2021

Volltextzugriff (PDF)

Pharmacological activation of the p53 pathway by nutlin-3 exerts anti-tumoral effects in medulloblastomas

Neuro-oncology (Charlottesville, Va.), 2012-07, Vol.14 (7), p.859-869

2012

Volltextzugriff (PDF)

What we learned from bench to bedside with the neuroblastoma targeting CD171-specific CAR

Klinische Pädiatrie, 2015, Vol.227 (3)

2015

Volltextzugriff (PDF)

ORAL N-ACETYLCYSTEINE LOWERS PLASMA HOMOCYSTEINE IN ADULTS ON A BACKGROUND OF ANABOLIC RESISTANCE TRAINING

JAR life, 2019, p.1-5

2019

Volltextzugriff (PDF)

What we learned from bench to bedside with the neuroblastoma targeting CD171-specific CAR

Molecular and cellular pediatrics, 2015-07, Vol.2 (Suppl 1), p.A22

2015

Volltextzugriff (PDF)

A regulatory BCL2 promoter polymorphism (-938C>A) is associated with outcome in neuroblastoma

Klinische Pädiatrie, 2010, Vol.222 (3)

2010

Volltextzugriff (PDF)

Pharmacologic activation of the p53 pathway using Nutlin-3 inhibits medulloblastoma cell proliferation in vitro

Klinische Pädiatrie, 2009, Vol.221 (3)

2009

Volltextzugriff (PDF)

RITA - p53 activation in medulloblastoma as a new approach for treatment?

Klinische Pädiatrie, 2012-04, Vol.224 (3)

2012

Volltextzugriff (PDF)

Molecular Targets in Embryonal Tumors

Klinische Pädiatrie, 2011-01, Vol.223 (1)

2011

Volltextzugriff (PDF)

High Thermostability and Lack of Cooperative DNA Binding Distinguish the p63 Core Domain from the Homologous Tumor Suppressor p53

The Journal of biological chemistry, 2001-10, Vol.276 (40), p.37390-37401

2001

Volltextzugriff (PDF)

Locoregional infusion of HER2-specific CAR T cells in children and young adults with recurrent or refractory CNS tumors: an interim analysis

Nature medicine, 2021-09, Vol.27 (9), p.1544-1552

2021

Volltextzugriff (PDF)

Joining Forces for Cancer Treatment: From "TCR versus CAR" to "TCR and CAR"

International journal of molecular sciences, 2022-11, Vol.23 (23), p.14563

2022

Volltextzugriff (PDF)

A Novel Glycoengineered Bispecific Antibody Format for Targeted Inhibition of Epidermal Growth Factor Receptor (EGFR) and Insulin-like Growth Factor Receptor Type I (IGF-1R) Demonstrating Unique Molecular Properties

The Journal of biological chemistry, 2014-07, Vol.289 (27), p.18693-18706

2014

Volltextzugriff (PDF)

The immune landscape of neuroblastoma: Challenges and opportunities for novel therapeutic strategies in pediatric oncology

European journal of cancer (1990), 2021-02, Vol.144, p.123-150

2021

Volltextzugriff (PDF)

CD171- and GD2-specific CAR-T cells potently target retinoblastoma cells in preclinical in vitro testing

BMC cancer, 2019-09, Vol.19 (1), p.895-17, Article 895

2019

Volltextzugriff (PDF)

Vγ9Vδ2 T Cells: Can We Re-Purpose a Potent Anti-Infection Mechanism for Cancer Therapy?

Cells (Basel, Switzerland), 2020-03, Vol.9 (4), p.829

2020

Volltextzugriff (PDF)

Pharmacodynamic and Antitumor Activity of BI 836880, a Dual Vascular Endothelial Growth Factor and Angiopoietin 2 Inhibitor, Alone and Combined with Programmed Cell Death Protein-1 Inhibition

The Journal of pharmacology and experimental therapeutics, 2023-03, Vol.384 (3), p.331-342

2023

Volltextzugriff (PDF)

Functional Tuning of CARs Reveals Signaling Threshold above Which CD8+ CTL Antitumor Potency Is Attenuated due to Cell Fas-FasL-Dependent AICD

Cancer immunology research, 2015-04, Vol.3 (4), p.368-379

2015

Volltextzugriff (PDF)

Reactivating TP53 signaling by the novel MDM2 inhibitor DS-3032b as a therapeutic option for high-risk neuroblastoma

Oncotarget, 2018-01, Vol.9 (2), p.2304-2319

2018

Volltextzugriff (PDF)

Synthetic Biodegradable Polymers

2012, 2012

Volltextzugriff (PDF)

The Spectrum of CAR Cellular Effectors: Modes of Action in Anti-Tumor Immunity

Cancers, 2024-07, Vol.16 (14), p.2608

2024

Volltextzugriff (PDF)

Widely applicable, extended flow cytometric stem cell enumeration panel for quality control of advanced cellular products

Scientific reports, 2022-10, Vol.12 (1), p.17995-17995, Article 17995

2022

Volltextzugriff (PDF)

Adoptive cell therapy in paediatric extracranial solid tumours: current approaches and future challenges

European journal of cancer (1990), 2023-11, Vol.194, p.113347-113347, Article 113347

2023

Volltextzugriff (PDF)

1 – 25 von 154

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(109)
Mit Volltextzugriff
(130)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

MYCN and ALKF1174L are sufficient to drive neuroblastoma development from neural crest progenitor cells

Advancement of the gold standard: ishage protocol combined with t and b cell analysis as mulitflex flow cytometry assay for standard cellular products and ATMPS

Pharmacological activation of the p53 pathway by nutlin-3 exerts anti-tumoral effects in medulloblastomas

What we learned from bench to bedside with the neuroblastoma targeting CD171-specific CAR

ORAL N-ACETYLCYSTEINE LOWERS PLASMA HOMOCYSTEINE IN ADULTS ON A BACKGROUND OF ANABOLIC RESISTANCE TRAINING

What we learned from bench to bedside with the neuroblastoma targeting CD171-specific CAR

A regulatory BCL2 promoter polymorphism (-938C>A) is associated with outcome in neuroblastoma

Pharmacologic activation of the p53 pathway using Nutlin-3 inhibits medulloblastoma cell proliferation in vitro

RITA - p53 activation in medulloblastoma as a new approach for treatment?

Molecular Targets in Embryonal Tumors

High Thermostability and Lack of Cooperative DNA Binding Distinguish the p63 Core Domain from the Homologous Tumor Suppressor p53

Locoregional infusion of HER2-specific CAR T cells in children and young adults with recurrent or refractory CNS tumors: an interim analysis

Joining Forces for Cancer Treatment: From "TCR versus CAR" to "TCR and CAR"

A Novel Glycoengineered Bispecific Antibody Format for Targeted Inhibition of Epidermal Growth Factor Receptor (EGFR) and Insulin-like Growth Factor Receptor Type I (IGF-1R) Demonstrating Unique Molecular Properties

The immune landscape of neuroblastoma: Challenges and opportunities for novel therapeutic strategies in pediatric oncology

CD171- and GD2-specific CAR-T cells potently target retinoblastoma cells in preclinical in vitro testing

Vγ9Vδ2 T Cells: Can We Re-Purpose a Potent Anti-Infection Mechanism for Cancer Therapy?

Pharmacodynamic and Antitumor Activity of BI 836880, a Dual Vascular Endothelial Growth Factor and Angiopoietin 2 Inhibitor, Alone and Combined with Programmed Cell Death Protein-1 Inhibition

Functional Tuning of CARs Reveals Signaling Threshold above Which CD8+ CTL Antitumor Potency Is Attenuated due to Cell Fas-FasL-Dependent AICD

Reactivating TP53 signaling by the novel MDM2 inhibitor DS-3032b as a therapeutic option for high-risk neuroblastoma

Synthetic Biodegradable Polymers

Extrachromosomal circular DNA drives oncogenic genome remodeling in neuroblastoma

The Spectrum of CAR Cellular Effectors: Modes of Action in Anti-Tumor Immunity

Widely applicable, extended flow cytometric stem cell enumeration panel for quality control of advanced cellular products

Adoptive cell therapy in paediatric extracranial solid tumours: current approaches and future challenges

Suchergebnisse filtern